Dan W Debonis, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 530 Melarkey St, Winnemucca, NV 89445 Phone: 775-623-5093 Fax: 775-623-9104 |
Dr. Jeremy Marc Keener, D.D.S. Dentist Medicare: Medicare Enrolled Practice Location: 15 Paradise Ave, Winnemucca, NV 89445 Phone: 775-625-7763 Fax: 775-623-9256 |
Kent R Henderson, D.D.S Dentist Medicare: Not Enrolled in Medicare Practice Location: 26 E Haskell St, D, Winnemucca, NV 89445 Phone: 775-623-5932 |
Dr. Rick L Grant, DMD Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 395 W Minor St, Winnemucca, NV 89445 Phone: 775-623-1228 Fax: 775-623-0774 |
Scott Maxmillian Forvilly, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 50 E Haskell St Ste C, Winnemucca, NV 89445 Phone: 775-623-4050 Fax: 775-623-0730 |
Dr. Jamie L Marvel, DDS Dentist Medicare: Medicare Enrolled Practice Location: 465 W Haskell St, Winnemucca, NV 89445 Phone: 776-623-2364 |
Susan Louise Jancar, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 50 E Haskell St, Winnemucca, NV 89445 Phone: 775-623-4050 |
Dr. Nathan Ezra Swensen, D.M.D Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 530 Melarkey St, Suite #9, Winnemucca, NV 89445 Phone: 775-623-5093 |
News Archive
IRIN examines efforts to tackle malnutrition amid increased food insecurity in Chad. "Like in the rest of the Sahel region, a mix of drought, poor rains and harvests as well as rising food prices have resulted in food insecurity and subsequent malnutrition," the news service writes, noting, "Chad's 'embryonic' economy is among factors limiting the local diversity of food sources and income, notes USAID's Famine Early Warning Systems Network (FEWS NET), adding that sociocultural care practices and poor health systems are also to blame."
The University of Birmingham has been awarded £1.78 million by the Wellcome Trust for research aimed at finding new therapies to treat diseases such as heart failure, diabetes and neurodegenerative disorders.
INSYS Therapeutics, Inc. announces positive results from the pivotal phase III efficacy trial for patients utilizing the Fentanyl Sublingual Spray technology to treat breakthrough cancer pain. All primary and secondary endpoints were achieved in the study, and the drug is the first product to ever show statistically significant pain relief when measuring the summary of pain intensity difference at five minutes in a phase III breakthrough cancer pain trial using Fentanyl.
Researchers have identified a mechanism that may keep a well known signaling molecule from eroding bone and inflaming joints, according to an early study published online today in the Journal of Clinical Investigation.
› Verified 8 days ago